Page 84 - IMO-1-1

Innovative Medicines & Omics Smp43 peptide

metalloproteinases (MMPs), thereby limiting cancer cell growth and survival, Smp43’s inhibition of ERK can reduce
invasion and metastasis. The NF-κB pathway also plays a the expression of metastasis-related genes like MMPs,
crucial role in inflammatory responses. Smp43’s ability to thereby limiting cancer cell invasion and spread. 26
reduce pro-inflammatory cytokine production could be In addition, the ERK/MAPK pathway plays a role
beneficial for treating chronic inflammatory conditions in inflammatory responses. Smp43 could reduce the
such as rheumatoid arthritis and inflammatory bowel production of pro-inflammatory cytokines and other
disease. In addition, by inhibiting NF-κB, Smp43 may mediators, offering potential benefits for inflammatory
impact the activation and differentiation of immune cells, diseases such as rheumatoid arthritis. By inhibiting ERK
such as T cells and macrophages, which are involved in activation, Smp43 may also affect the function of immune
autoimmune responses. 6,16 cells, such as T cells and macrophages, which are involved
Previous Studies in various cell lines have provided in inflammation. The ERK/MAPK pathway is also crucial
insights into how Smp43 affects the NF-κB pathway, for neuronal survival and function. Smp43 might influence
including changes in IκB phosphorylation, NF-κB nuclear synaptic plasticity and memory formation by modulating
translocation, and target gene expression. Detailed analyses ERK-dependent signaling in neurons. 14
of signaling pathways in response to Smp43 treatment have
helped clarify the peptide’s mechanisms of action. Research 3. Effects of Smp43
using animal models of cancer, inflammatory disorders, 3.1. Smp43’s effect on cancer cells: Positive effect
and neurodegenerative diseases is crucial for assessing the Smp43, derived from scorpion venom, has garnered
systemic effects of Smp43 on the NF-κB pathway and its significant attention for its potential anticancer effects.
potential therapeutic benefits. In vivo, studies are necessary Smp43 interacts with various cellular mechanisms in
to evaluate the efficacy and safety of Smp43 as a therapeutic cancer cells, highlighting its promising therapeutic
agent. Smp43 could potentially be developed as a novel potential. It can trigger apoptosis through the intrinsic
treatment for cancers with aberrant NF-κB activation. 8,24 mitochondrial pathway by increasing mitochondrial
2.5.4. ERK/MAPK pathway membrane permeability, leading to cytochrome c release
and subsequent caspase activation. In addition, Smp43 may
The ERK/MAPK pathway is a vital signaling mechanism promote apoptosis through the extrinsic death receptor
that governs cellular processes such as proliferation, pathway by upregulating death receptors such as FAS and
differentiation, and survival. Abnormal activation of this TRAIL-R, which activate caspase-8. Smp43 is also capable
pathway is linked to various diseases, including cancers, of inducing cell cycle arrest at various checkpoints (G1, S, or
inflammatory disorders, and developmental conditions. G2/M phases), thereby inhibiting cancer cell proliferation.
Smp43 may inhibit the interaction between RAS and This arrest is mediated by the regulation of cyclins and
RAF, thus blocking RAF kinase activation. This inhibition cyclin-dependent kinases. Furthermore, Smp43 can cause
disrupts the phosphorylation cascade necessary for DNA damage by activating the DNA damage response
activating ERK. In addition, Smp43 might directly inhibit pathway, which halts cell division and encourages apoptosis.
MEK1/2 (MAPK/ERK kinase), which is responsible for the Smp43 also reduces cancer cell metastasis by inhibiting
activation of ERK1/2 through phosphorylation. 25 migration and invasion, achieved by downregulating
By reducing the phosphorylation of ERK1/2 at critical MMPs and other proteins involved in extracellular matrix
activation sites (Thr202/Tyr204 for ERK1 and Thr185/ breakdown. The peptide may also inhibit epithelial-to-
Tyr187 for ERK2), Smp43 prevents ERK activation. mesenchymal transition (EMT), a process that enhances
The peptide may also impede the translocation of cancer cell mobility and invasiveness, by regulating EMT
phosphorylated ERK1/2 into the nucleus, thereby limiting markers such as E-cadherin, N-cadherin, and vimentin. 12
their ability to activate transcription factors that regulate Smp43 can interfere with angiogenesis, the formation
gene expression. This inhibition of ERK1/2 can affect the of new blood vessels that supply tumors with nutrients and
activation of transcription factors such as ELK-1, c-FOS, oxygen. This effect is mediated by downregulating pro-
and c-MYC, leading to changes in gene expression. angiogenic factors, such as vascular endothelial growth
Furthermore, Smp43 can influence the expression and factor and its receptors. Furthermore, Smp43 inhibits the
activity of cell cycle regulators like cyclin D1, impacting ERK/MAPK pathway, reducing cancer cell proliferation
cell growth and proliferation. By blocking the ERK/MAPK and survival, and affects the NF-κB pathway, leading to
pathway, Smp43 has the potential to decrease cancer cell decreased expression of genes involved in inflammation,
proliferation and induce apoptosis. Since this pathway is proliferation, and survival, thereby reducing cancer cell
frequently overactive in cancers, contributing to tumor growth and promoting apoptosis. Previous studies involving

Volume 1 Issue 1 (2024) 78 doi: 10.36922/imo.4353